Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/71528
Citations
Scopus Web of Science® Altmetric
?
?
Type: Conference paper
Title: Pilot study of biomarkers of chemotherapy-induced Gastrointestinal Toxicity
Author: Al-Dasooqi, N.
Mayo, B.
Bowen, J.
Stringer, A.
Gibson, R.
Keefe, D.
Citation: Asia Pacific Journal of Clinical Oncology, 2011; 7(Supp 4): p.154
Publisher: Blackwell Publishing Ltd.
Publisher Place: United Kingdom
Issue Date: 2011
ISSN: 1743-7555
Conference Name: Clinical Oncological Society of Australia Annual Scientific Meeting (38th : 2011 : Perth, Western Australia)
Statement of
Responsibility: 
N. Al-Dasooqi, B. Mayo, A. Stringer, R. Gibson, J. Bowen, D. Keefe
Abstract: Chemotherapy regimens containing 5-fl uorouracil, capecitabine or irinotecan are commonly associated with severe gastrointestinal toxicity. A predominant adverse event of these agents is complicated diarrhoea. There are currently no satisfactory ways to predict patients most at risk of developing diarrhoea during treatment, or adequate early markers to signal impending problems. As such, this pilot study investigated potential biomarkers of therapy-induced diarrhoea. Patients scheduled to receive anti-cancer regimens containing 5-fl uorouracil, capecitabine or irinotecan were recruited from a single institution. Patient blood and stool samples were collected before starting, and on day 2, 5, and 10 of one chemotherapy cycle. Serum extracellular matrix proteins, MMP-2, -3 and -9, and pro-infl ammatory cytokines, TNF-alpha, Il-1B and NFkB were assayed by ELISA. Fecal DNA was extracted and examined for Bifi dobacterium and Ecoli microfl ora gene expression. Time course data was grouped to assess overall changes in biomarkers levels. Patient data was also paired, where possible, to observe inter-individual variability. All data presented as mean ± SEM. Sixteen patients participated in the study between April 2009 and July 2009. All patients provided at least one blood and stool sample. MMP3 increased 5.74-fold from baseline on day 2 (0.303 ± 0.98 vs 1.740 ± 0.71 ng/ml). NFkB levels showed a peak increase of 4.51-fold from baseline on day 2 (0.190 ± 0.16 vs 0.856 ± 0.63) and TNFa rose 6.38-fold on day 10 (0.929 ± 0.89 vs 5.932 ± 4.90 pg/ml). Potentially pathogenic microfl ora, Ecoli, was increased 5.16-fold from baseline on day 10 (0.028 ± 0.008 vs 0.146 ± 0.07). All other biomarkers remained relatively unchanged. Our preliminary fi ndings suggest that MMP3, NFkB, TNFa and Ecoli are potential biomarkers of gastrointestinal toxicity induced by specific chemotherapy agents. Further analysis is required to determine if biomarker levels correlate with patient symptoms. Confi rmation of these fi ndings in a larger cohort would enable improved detection of pre-toxic patients allowing early interventions for chemotherapy-induced diarrhoea.
Description: Abstract no. 331
Rights: © 2011 Blackwell Publishing Asia Pty Ltd
RMID: 0020119089
DOI: 10.1111/j.1743-7563.2011.01472.x
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.